eptinezumab is in phase iii trials. its maker plans to submit an application with the fda later this year. it is for chronic migraine prevention.
.
lea ament, left, and tamara nunley talk about the care their team provided for helen and robert valenzuela at st. jude medical center in fullerton. (scott smeltzer / staff photographer)
.
.
.
mainstream reporters and editors and publishers are well aware that telling the truth and continuing to pound on it would undermine a basic institution of society.
.
of all car-t cell trials registered since 2001, more than half are being conducted in china.
.
.
.
.